The predictable failure of trilaciclib
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
ALX looks to surprise again
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
Tempest’s pivotal amezalpat conundrum
How does the micro-cap biotech now finance a 700-patient phase 3 study?
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
Can Wee1 be both alive and dead? Schrödinger hopes so
The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.
